To illustrate the potential of the platform, we used 40 FRET biosensors in a single experiment and we profiled a cancer-relevant signaling network by monitoring: (1) the perturbation of epidermal growth factor receptor (EGFR) signaling caused by the activating mutation L858R and the resistance mutation T790M of EGFR, (2) the effects of an MEK inhibitor on EGFR network activity; and (3) the crosstalk of the EGFR and insulin-like growth factor-1 receptor (IGF-1R) signaling networks. The gene discussed is EGFR; the disease is cancer.